Compare · ALKS vs NVO
ALKS vs NVO
Side-by-side comparison of Alkermes plc (ALKS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALKS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 25.9x ALKS ($7.08B).
- Over the past year, ALKS is up 36.3% and NVO is down 45.7% - ALKS leads by 82.0 points.
- ALKS has been more active in the news (18 items in the past 4 weeks vs 8 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Alkermes plc
- Novo Nordisk A/S
- Price
- $42.43-0.86%
- $41.01-4.51%
- Market cap
- $7.08B
- $183.15B
- 1M return
- +19.82%
- -10.44%
- 1Y return
- +36.30%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1991
- News (4w)
- 18
- 8
- Recent ratings
- 25
- 25
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALKS
- EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $87,564 worth of Ordinary Shares (2,034 units at $43.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 229,524 units (SEC Form 4)
- Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
- Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- EVP R&D, Chief Medical Officer Hopkinson Craig C. sold $375,044 worth of Ordinary Shares (9,000 units at $41.67) as part of a pre-agreed trading plan and exercised 5,000 units of Ordinary Shares at a strike of $19.34, decreasing direct ownership by 5% to 77,389 units (SEC Form 4)
- VP, Finance (Interim PAO) Parisi Samuel Joseph sold $687,007 worth of Ordinary Shares (16,217 units at $42.36) and exercised 16,217 units of Ordinary Shares at a strike of $19.48 (SEC Form 4)
- Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
- Director Wright Christopher I converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 20% to 27,680 units (SEC Form 4)
- Director Wilson Frank Anders covered exercise/tax liability with 1,475 units of Ordinary Shares and converted options into 6,142 units of Ordinary Shares, increasing direct ownership by 15% to 35,751 units (SEC Form 4)
- Director Snyderman Nancy Lynn Md converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 44% to 15,395 units (SEC Form 4)
- Director Mckeon Brian P converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 14% to 38,536 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care